News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …
Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …
Minerva Neurosciences (NERV) has promoted Anthony Aliquo to Chief Accounting Officer and principal accounting officer, effective August 10, 2026. This move includes an increase in his annual base salary to $296,696 and a performance bonus target of 35%. Frederick Ahlholm remains the Chief Financial …
HC Wainwright has revised its Q3 2026 EPS estimate for Minerva Neurosciences (NASDAQ:NERV) to a loss of $0.14 per share, a significant reduction from its previous forecast of a $0.01 loss. The firm also projects a $0.50-per-share loss for the full fiscal year 2026, …
H.C. Wainwright has reiterated its Hold rating for Minerva Neurosciences (NERV.US) and maintained a target price of $7. This indicates the firm's continued neutral outlook on the company's stock performance.
Wall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from a "sell" to a "hold" rating. The biopharmaceutical company reported a quarterly loss of $0.14 per share, surpassing analyst expectations for a $0.19 loss. Despite the upgrade, NERV shares were trading down 3.8% at $4.27, well …
This article reports on the filing of a Form 8K by Minerva Neurosciences Inc. on August 7. It includes a brief mention of the company's stock symbol and a slight decrease in its share price. The content primarily serves as an announcement for the …
Minerva Neurosciences reported a GAAP net income of $17.5 million for Q2 2026, largely due to a non-cash gain on a warrant liability, with cash and equivalents standing at $75.4 million. The company is advancing a global confirmatory Phase 3 trial for roluperidone, with …
Minerva Neurosciences (NERV) reported its Q2 2026 financial results, showing a narrower loss of $0.14 per share, an improvement from $0.43 in Q2 2025. The company posted a net income of $17.5M, reflecting progress in managing R&D spending while advancing its CNS therapies. Analysts …
Minerva Neurosciences, Inc. reported a net income of $17.47 million for Q2 2026, a significant improvement from a loss in the previous year, with diluted loss per share narrowing to $(0.14). The company initiated its C19 Phase 3 trial for roluperidone, increased R&D spending, …
Minerva Neurosciences (NERV) announced a Q2 2026 GAAP net income of $17.5 million. The company's Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia, is ongoing, with topline efficacy data expected in mid-2027 and mid-2028 for its two phases. The report also detailed …
Minerva Neurosciences reported a Q2 2026 GAAP net income of $17.5 million, or $0.36 per basic share, primarily due to a $27.6 million non-cash gain from a warrant liability fair value change. Despite this, the adjusted non-GAAP net loss widened to $7.8 million, reflecting …
Minerva Neurosciences (NERV) reported the grant of 12,147 stock options to director Inderjit Kaul, with an exercise price of $3.97 and an expiration date of August 2, 2036. The options' vesting is performance- and time-based, with significant portions contingent on the success of a …
This article announces the filing of a Form 4 for Minerva Neurosciences Inc. on August 3rd. It indicates that this is an insider trading report, suggesting that company insiders have bought or sold shares. The article also provides the stock's current performance (NERV +2.02%).
Minerva Neurosciences, Inc (NERV) is projected to announce its Q2'26 earnings on August 4, 2026, with an estimated revenue of $0 and an EPS of ($0.19). This article provides a brief overview of the upcoming financial disclosure, including historical and estimated revenue and EPS …
TradingKey assesses Minerva Neurosciences Inc. (NERV) with a financial score of 7.28, placing it 134th out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis highlights that key data for detailed metrics like cash …
Minerva Neurosciences Inc. (NERV) has a relatively healthy fundamental outlook with high growth potential, though its valuation is considered fair. Analysts have rated the stock as 'Hold' with a target price of $9.50, suggesting a potential upside of 138.69%. The company, a clinical-stage biopharmaceutical …
This article provides a detailed historical cash flow statement for Minerva Neurosciences Inc (NERV), including operating, investing, and financing cash flows from FY2012Q4 through FY2026Q1. It also includes frequently asked questions defining different types of cash flow and NERV's recent performance. The company generated …
This article provides an overview of Minerva Neurosciences Inc.'s (NERV) dividend and stock split history. It notes that the company has distributed no dividends in the past five years and details an 8-to-1 merger-related stock split that occurred on June 17, 2022. The current …
This article provides an overview of Minerva Neurosciences Inc. (NERV)'s shareholder structure, detailing its major shareholders and institutional holdings. It lists the top individual shareholders and their proportions, as well as a breakdown of shareholder types such as hedge funds, investment advisors, and venture …
This page on TradingView provides financial information for Minerva Neurosciences Inc. (FWB:4MNA) traded on the Frankfurt Stock Exchange. It includes an overview of fundamentals and stats, with sections for statements, statistics, dividends, earnings, and segment performance. The content indicates the market is closed with …
Minerva Neurosciences Inc (NERV) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion has seen a significant quarter-over-quarter increase of 275.59%, now at 71.95%. James Simons is noted as the largest institutional …
Search by ticker symbol or company name and select a result to open its chart.